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Abstract
Central giant cell lesion (CGCL) is a benign lesion which has unpredictable biologic behaviour and is amenable to 
a plethora of treatment alternatives. We describe our experience in managing this lesion by intralesional triamci-
nolone.  
The mainstay of treatment of CGCL in our centre until now has been surgical curettage or resection. We chose 
two patients for this pilot endeavour at our hands. Case I is a 10 year old girl having CGCL of left side mandible. 
Case II is a 20 yr old man with CGCL affecting the left side posterior mandible. Both patients responded well 
to intralesional administration of triamcinolone acetonide (Kenacort-10®) with no obvious recurrences to date. 
Successful application of this conservative drug therapy for managing CGCL can not only save the patient from a 
mutilating procedure but also has significant financial implications. The amount of triamcinolone injected ranged 
from 85mg to 180mg by 5-6 injections at weekly intervals.
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Introduction
Successful nonsurgical management of a pathology which 
clamors for surgical intervention at first impression is 
a “cause celebre” for all concerned. Central giant cell 
lesion (CGCL) is a benign lesion which has variable and 
unpredictable biologic behaviour and is amenable to a 
plethora of treatment alternatives, both surgical as well 
as conservative (1, 2). Although the surgical alternative 
eliminates the pathology almost instantaneously one 
must look upon the other perspective of its consequent 
morbidity. In conservative management various agents 
have been used with variable response like intralesional 
steroids (3-11), systemic calcitonin (12-16) (intralesional, 
subcutaneous) and intralesional interferon-α (17, 18). We 
present our experience in the management of CGCL by 
conservative means. The mainstay of treatment of CGCL 
in our centre to date has been surgical curettage or resec-
tion. Based on the increasing number of case reports in 
the literature promoting the use of conservative therapy, 
we decided to employ it in our cases. Two patients were 
subjected to this pilot endeavor and intralesional steroids 
were the preferred modality. We used triamcinolone 
acetonide 10mg/ml and lignocaine 2% with adrenaline 
1:200,000 (50:50) at the dose of 1ml of the solution for 
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every 1cm of radiolucency,as determined on an ortho-
pantomogram (OPG).
Case Reports
Case 1
A 10-year-old girl was referred to our centre in August 
2006 with the chief complaint of progressively increasing 
swelling of left side of lower jaw. The swelling had been 
present for 6 months and had recently started increasing 
in size with pain in the affected region. On examination 
there was a clear asymmetry of anterior mandible and 
chin region on the left side. There was no paresthesia 
over the lower lip. No positive history of trauma could 
be elicited from the patient. Intraorally the swelling had 
obliterated the lower labial vestibule from midline to the 
left 1st premolar. On palpation it was firm and tender. 
The teeth numbers 31, 32 were rotated. Orthopantomo-
graph (OPG) showed a well circumscribed radiolucency 
from teeth number 42 to 35 (Fig. 1). The borders were 
corticated and multilocular with 3 areas of increased 
radiolucency suggestive of bicortical perforation. The 
lesion measured 3 x 2.5 cm in maximum dimensions on 
the OPG. Aspiration of the lesion yielded frank blood. 
Incisional biopsy was performed and the diagnosis was 
CGCL. Normal Parathormone assay ruled out hyper-
parathyroidism. Considering the age of the patient, 
intralesional steroid was the chosen modality. Treatment 
was started with 4ml mixture of kenacort – 10® (2ml) + 
lignocaine 2% with adrenaline 1:200,000 (2 ml). After 
the 2nd injection the lesion started shrinking in size and 
became painless. Subsequently the amount of solution 
injected was progressively reduced. By the last injection 
at 5 weeks, it was difficult to penetrate the labial cortex 
and extreme pressure was required to administer even 
1ml of the mixture. The total dose of triamcinolone ad-
ministered was 85mg over five weeks in increments of 
4 injections of  20mg each followed by the last injection 
of approximately 5mg. OPG taken 1 week after the last 
injection showed increasing radiopacity in the lesion.  By 
the next month opacity was evident in the centre of the 
lesion with minimal radiolucency at the periphery. OPG 
taken 3 months after the last injection showed blurring of 
the lesion margins with new bone formation. At 6 months 
the bony architecture was near normal and only minimal 
radiolucency was present around the root apices of the 
involved teeth. Eighteen months after the last injection 
there was no sign indicative of any previous lesion in 
symmetrical, normal growing mandible with normal 
teeth alignment (Fig. 2). 
Case 2
A 20-year-old male reported to our centre in December 
2006 with the chief complaint of swelling on the left side 
of face at the angle ramus region. The swelling was noted 
about 4 months previously and was slowly increasing in 
Fig 2b. Post injection OPG (13 months) showing 
complete radioopacity at the lesion site (case 2).  
Fig 1a. OPG showing radiolucent lesion ex-
tending from midline to teeth number 35 with 
displacement of teeth (case 1).
Fig 1b. Post injection OPG (18 months) showing 
normal bony trabecular pattern and well aligned 
teeth at the previous lesion site (case 1).
Fig 2a. OPG showing radiolucency in relation to 
teeth number 35 to distal of teeth number 38 and 
destruction of alveolus and inferior border of 
mandible (case 2).
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size. No history of trauma or clinical features pertaining 
to hyperparathyroidism was noted. The swelling was lo-
cated on the left body and ramus region of mandible with 
expansion of the involved inferior and posterior border. 
The swelling was hard all over except at its superior limits 
in the vicinity of the alveolus. There was no paresthe-
sia in the region and mouth opening was normal. OPG 
showed a mixed lesion extending from distal of 35 to 38. 
The alveolus around 37 was resorbed. There were septae 
present inside the lesion dividing it into 3 compartments 
(Fig. 3). The inferior border of mandible was expanded 
and destroyed and the lesion measured 5 x 4 cm on the 
OPG. On aspiration the lesion yielded frank blood. Inci-
sional biopsy performed under local anaesthesia showed 
histopathological picture consistent with CGCL. Intrale-
sional triamcinolone acetonide (10mg/ml) was injected 
in similar manner using the same protocol. Injection was 
started with 6 ml mixture and total six such injections 
were given at weekly intervals. OPG taken after six weeks 
showed increasing radio opacity within the lesion and so 
further injections were stopped. Radiographs taken at 
3 monthly intervals displayed progressively increasing 
trabeculations. Ten months after the last injection this 
patient complained of tenderness at one point which was 
observed to be a radiolucent area (1x 2 cm) on OPG. It was 
decided to administer the mixture to the specific site as 
it was easily localizable and accessible. 2ml of the same 
mixture was injected thrice at weekly intervals. Three 
months later (total 13 months after initiation of therapy) 
the lesion was completely radio opaque and the patient 
was entirely symptom free (Fig. 4). The total dose of 
triamcinolone administered was 180mg during the initial 
session of 6 weeks followed by 30mg in second session 
over 3 weeks. The residual bulge at the inferior border 
can be surgically recontoured although the patient is 
unwilling at present.
Discussion
Central giant cell lesion usually presents as a painless, 
slow growing swelling of the jaw. Displacement of teeth 
occurs frequently and can lead to malocclusion (19). 
Radiological findings are diverse ranging from small 
unilocular lesions to large multilocular lesions with well 
defined or ill defined borders (20). Also seen are displace-
ment of teeth and tooth germs, root resorption and cortical 
perforation (19).  Presence of a wispy opacification within 
the lesion is the most significant radiographic sign asso-
ciated with CGCL (21). Choung et al. (22) differentiated 
between aggressive and non aggressive lesions on the 
basis of signs and symptoms and histological features. 
Aggressive lesions are characterized by one or more of 
the following features: large size (> 5 cm), pain, paresthe-
sia, root resorption, rapid growth, cortical perforation and 
a high recurrence rate after surgical curettage. The non 
aggressive form is characterized by a slow, almost asymp-
tomatic growth that does not perforate the cortical bone 
or induce root resorption and has low recurrence rate. 
Both the patients reported by us can be categorized as 
non aggressive forms. CGCL is composed of two distinct 
populations of cells viz. multinucleated giant cells and 
spindle shaped stromal cells. The latter are thought to be 
proliferating tumor cells based on available evidence (23, 
24). These are osteoblast like cells with similar functions. 
They induce osteoclast formation from mononuclear 
blood cells via RANK- RANKL interaction. RANKL 
(receptor activator of nuclear factor kb ligand) present on 
stromal cells influences the differentiation of giant cells 
from RANK expressing mononuclear cells (25). 
Both steroids as well as calcitonin affect the giant cells 
rather than the prime neoplastic cells i.e. the stromal 
cells. Dexamethasone inhibits lacunar resorption by 
mature osteoclasts isolated from giant cell tumor of the 
bone by probably inhibiting the extracellular production 
of bone resorption mediating lysosomal proteases and by 
inducing apoptosis of osteoclastic cells (26-29). Recently, 
glucocorticoid receptors and calcitonin receptors have 
been identified on both the mononuclear spindle shaped 
cells as well as the multinucleated giant cells (2,30 – 33). 
These receptors may govern the choice of nonsurgical 
therapy i.e. steroids or calcitonin or both. Surgery is 
always left as a salvage option in nonresponsive or re-
current lesions.
On reviewing the literature we have found a total of 15 
cases reported which were treated by intralesional cor-
ticosteroid with variable response (Table I). Majority of 
cases were given 6 injections but the range was 4 – 20 
injections. Out of the total 15 cases only 3 required sur-
gical interventions for residual radiolucency. Majority 
of authors observe a protocol of giving 6 injections and 
following up the patients with periodic radiographic 
examination and intervening only if symptomatic ra-
diolucency is observed. Most of the authors have used 
triamcinolone acetonide as 50% mixture with local 
anaesthesia with adrenaline. However, no reason for 
this choice has been mentioned by any author. Triam-
cinolone is a 9α derivative of prednisolone with highly 
selective glucocorticoid activity without significant 
mineralocorticoid action. It is short acting with plasma 
half life of 200min and biological half life of 18 – 36 
hours. Although its absorption from the site of deposition 
is minimal resulting in negligible systemic side effects 
if at all. Even then prior to this therapy, the occurrence 
of systemic contraindication to steroid administration 
like diabetes, peptic ulcer, known allergy to steroids and 
more so the presence of local infection should be ruled 
out (3,5,8,10). The astute operator will become aware of 
a responsive lesion with each passing week by looking 
for the following (3):
1. Increasing difficulty in penetration of needle into the 
lesion.
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2. Back pressure felt while injecting, resulting in lesser 
amount of solution injected in the later stages.
3. Decreased swelling and pain.
4. The radiographs will show enhancing radioopacity 
within the lesion.
We opted for steroids as the modality for our patients 
because of the following advantages:
1. Ease of administration and less invasive (7)
2. Relatively short duration of treatment (6 weeks 
average compared to 3 - 27 months for calcitonin and 
interferon-α)
3. Relatively higher success rate as compared to calcitonin 
/interferon- α 
4. Cheaper
5. Easily available 
6. Minimal systemic side effects
7. No crippling effects on developing dentition as seen 
in our cases
8. The option to treat surgically or by other alternative 
conservative treatments in future if necessary (3).
Disadvantages of steroids:
1. Unpredictable response when compared to surgical 
option as the first choice
2. Failure to target the prime neoplastic cells i.e. spindle 
shaped stromal cells.
3. Healing occurs by fibrocollagenous tissue formation 
which later ossifies. This fibrous tissue may misguide the 
clinician as probable recurrence/ residual lesion (3, 9).
The unpredictable response can be minimized by recep-
tor typing prior to submitting a patient to a particular 
conservative modality. Despite the failure to target the 
neoplastic cell clinical response has time and again de-
monstrated the effectiveness of these therapy options. 
Thus successful management of these two patients has 
illustrated the efficacy of intralesional steroid therapy 
for the CGCL of the mandible.
Year Author No. of cases Site Size
No. of 
injections Result
1994 Terry & Jacoway (3) 4
Right Mandible _ 6 Complete resolution 3years
Left Mandible _ 6 Complete resolution 16 months
Right Anterior Mandible _ 6 Complete resolution 26 months
Left Posterior mandible _ 6 Incomplete resolution 
1994 Kermer et al. (4) 1
Right Mandible body 3cm 6 Complete resolution 3years
1998 Rajeevan  and Soumithran(5) 1
Midline Mandible _ 6 Resolution
2000 Khafif et al.(6) 1 Complete resolution 24 months
2001 Kurtz et al.(7) 1
Midline Mandible
5X3 cm 6 + 6
Recurrence at 1 
year followed by 
Complete resolution 
1year
2001 Adornato and Kenneth(8) 1
Left Mandible 3 X 3cm 6 Partial resolution 7 months
2002 Carlos and Sedano(9) 4
Right Maxillary 
tuberosity 4 cm 20
Complete resolution 
7 years
Mandibular body 4 cm 17 Complete resolution 6years
Midline hard palate 5 cm 4 Residual lesion 15 months
Left Body of Mandible _ 4 Complete resolution 2years
2005 Sezer et al. (10) 1 Left Body of Mandible 3.5 X 2 cm 6 Complete resolution 3years
2005 Abdo et al. (11) 1 Left Parasymphysis _ 3 Complete resolution 18 months
Table I.  Reported cases managed by intralesional steroid injection.
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